Cost effectiveness analysis in cystic fibrosis.
Doran
Chris
C
Vos
Theo
T
D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000191:economics / Q000382:microbiology*; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology*
D000900:Anti-Bacterial Agents